MML Investors Services LLC Has $1.66 Million Position in Inspire Medical Systems, Inc. (NYSE:INSP)

MML Investors Services LLC increased its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 8.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,874 shares of the company’s stock after purchasing an additional 625 shares during the quarter. MML Investors Services LLC’s holdings in Inspire Medical Systems were worth $1,662,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the stock. Hodges Capital Management Inc. acquired a new stake in shares of Inspire Medical Systems during the third quarter worth approximately $633,000. Northeast Financial Consultants Inc acquired a new stake in Inspire Medical Systems in the third quarter valued at approximately $274,000. State Street Corp lifted its stake in Inspire Medical Systems by 78.0% in the third quarter. State Street Corp now owns 1,049,784 shares of the company’s stock valued at $221,557,000 after acquiring an additional 459,990 shares during the last quarter. SYM FINANCIAL Corp acquired a new stake in Inspire Medical Systems in the third quarter valued at approximately $273,000. Finally, Quarry LP lifted its stake in Inspire Medical Systems by 30.9% in the third quarter. Quarry LP now owns 449 shares of the company’s stock valued at $95,000 after acquiring an additional 106 shares during the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $260.00 target price on shares of Inspire Medical Systems in a research note on Tuesday, November 5th. Stifel Nicolaus reiterated a “hold” rating and issued a $200.00 target price (up from $170.00) on shares of Inspire Medical Systems in a research note on Tuesday, November 5th. Bank of America upgraded shares of Inspire Medical Systems from a “neutral” rating to a “buy” rating and lifted their target price for the company from $220.00 to $255.00 in a research note on Wednesday, November 20th. Wells Fargo & Company lifted their target price on shares of Inspire Medical Systems from $187.00 to $198.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Finally, Truist Financial reiterated a “buy” rating and issued a $240.00 target price (up from $217.00) on shares of Inspire Medical Systems in a research note on Monday, September 30th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $233.58.

Inspire Medical Systems Stock Up 1.0 %

NYSE:INSP opened at $190.71 on Wednesday. Inspire Medical Systems, Inc. has a 12 month low of $123.00 and a 12 month high of $257.40. The firm has a market cap of $5.72 billion, a price-to-earnings ratio of 178.23 and a beta of 1.31. The company’s 50 day moving average is $193.62 and its 200-day moving average is $179.30.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, November 4th. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.54. The business had revenue of $203.20 million for the quarter, compared to analyst estimates of $197.59 million. Inspire Medical Systems had a net margin of 4.37% and a return on equity of 5.30%. Inspire Medical Systems’s revenue was up 32.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.29) earnings per share. Research analysts predict that Inspire Medical Systems, Inc. will post 1.33 EPS for the current fiscal year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.